| NEUIGKEITEN | BIOGRAPHIEN | EVENTS | FIS INTERN | MARKETING | MEDICAL | |
LANGLAUF
SKISPRINGEN
NORDIC COMBINED
SKI ALPIN
FREESTYLE
SNOWBOARD
ANDERE
SPEED SKIING
GRASSSKI
TELEMARK
MASTERS
KALENDER
RESULTATE
STATISTIKEN
LIVE TIMING
FIS HISTORY
Recent FIS News
Below you will find a listing of recent FIS News
Find your news
WADA approves List 2012
The World Anti-Doping Agency (WADA) has approved the List of Prohibited Substances and Methods for 2012 at its Executive Committee Meeting hosted by the IOC in Lausanne, Switzerland. The new List will be made official and published by 1st October, and will take effect on 1st January 2012.
As one of the cornerstones in the global fight against doping, the annually reviewed List specifies substances and methods prohibited in sport, and it is a mandatory document for all organizations that have adopted the World Anti-Doping Code.
"Keeping abreast of scientific advances and taking on board recommendations from our stakeholders is a key part of WADA's role when updating the List, which is required to happen on an annual basis due to our expanding knowledge of doping," said WADA President John Fahey. "The revision process has been developed and refined over the eight years that WADA has been responsible for the List, and we are confident that we have the necessary expert contributions and checks and balances within the process to make it as comprehensive and robust as possible.
Following requests from stakeholders for additional guidance on what constitutes best practice for testing programs, WADA has advised that there needs to be more emphasis on the collection of blood samples.
On average only 4% of all doping control samples collected across all anti-doping organizations in 2010 was for blood, and most of these were for passport programs. This has been a key concern for WADA since an Anti-Doping Organization (ADO) ought to collect blood as it cannot purport to have an effective program in place if there is a loophole in its testing program leaving for possible abuse of substances and methods that cannot be detected in urine analysis such as human Growth Hormone and blood transfusions. A recommendation was therefore made to the Executive Committee that all ADOs ensure that not less than 10% of all samples collected are blood specimens. This recommendation was accepted by the Executive Committee which recognized that by increasing blood collection an ADO can focus resources in a targeted and intelligent fashion, and put quality testing ahead of quantity.
Contributed by WADA